Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Effects of Bacille Calmette-Gu?rin after the first demyelinating event in the CNS
- Robert Lisak, Neurology, Wayne State University Medicalrlisak@med.wayne.edu
Submitted February 24, 2014 - The cost effective way to increase effectiveness of immuno-modulation
- Kah Fang Khoo, Consultant Physician, Tanjung Medical Centrefangpenang@gmail.com
Submitted February 24, 2014 - BCG and EBV status
- Giovanni Ristori, Researcher, Center for Experimental Neurological Therapies, S. Andrea Hospital-site, Neurosciences, Mental Healtgiovanni.ristori@uniroma1.it
- Giovanni Ristori, Rome, Italy; Silvia Romano, Rome, Italy; Giulia Coarelli, Rome, Italy; Maria Chiara Buscarinu, Rome, Italy; Marco Salvetti, Rome, Italy
Submitted February 19, 2014 - BCG vaccination may restore normal Notch signaling, which is disrupted in MS, possibly due to infection by Epstein-Barr virus causing auto-immunity
- Steven R Brenner, Physician, St. Louis University Dept. Neurology and Psychiatry, retired.SBren20979@aol.com
Submitted January 28, 2014 - BCG: to vaccinate may be better.
- Giovanni Ristori, researcher, Center for Experimental Neurological Therapies, S. Andrea Hospital-site, Neurosciences, Mental Healtgiovanni.ristori@uniroma1.it
- Silvia Romano, Rome, Italy; Giulia Coarelli, Rome, Italy; Maria Chiara Buscarinu, Rome, Italy; Marco Salvetti, Rome, Italy
Submitted January 22, 2014 - BCG: to vaccinate or not?
- Nitin K. Sethi, Assistant Professor of Neurology, New York-Presbyterian Hospital, Weill Cornell Medical Center 525 East 68th Street, New York, NY 1006sethinitinmd@hotmail.com
- Nitin K Sethi, New York, NY
Submitted January 09, 2014
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSD. H. Miller, D. Soon, K. T. Fernando et al.Neurology, April 23, 2007 -
Articles
Gray and white matter volume changes in early RRMSA 2-year longitudinal studyM. Tiberio, D. T. Chard, D. R. Altmann et al.Neurology, March 21, 2005 -
Articles
Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trialsDavid Bates et al.Neurology, December 27, 2010 -
Articles
Early MRI in optic neuritisThe risk for disabilityJ. K. Swanton, K. T. Fernando, C. M. Dalton et al.Neurology, February 09, 2009